Research question

Is TB-500 the same as thymosin beta 4?

Closely related but not identical. TB-500 is a synthetic 17-amino-acid acetylated fragment of the full-length 43-amino-acid thymosin β4 protein, containing the LKKTETQ actin-binding motif. Most research-supply contexts use TB-500 interchangeably with full-length thymosin β4 for the actin-binding pharmacology, but treating them as fully equivalent is an assumption rather than a proven equivalence.

What the research literature says

Full-length thymosin β4 is a 43-amino-acid intracellular protein, one of the most abundant polypeptides in mammalian cells, with primary function as a G-actin-sequestering protein maintaining the monomeric-actin pool available for cytoskeletal remodelling. The Yarmola work characterised the ternary complex of profilin, thymosin β4, and actin that underlies the sequestration mechanism (PMID 11579089).

TB-500 in research-supply form typically refers to a synthetic acetylated fragment containing the actin-binding domain — the LKKTETQ motif and surrounding residues — rather than the complete 43-amino-acid protein. The fragment retains the actin-binding pharmacology (the primary mechanism characterised across the published research literature) and is significantly easier and cheaper to synthesise than the full-length protein.

Published research using full-length thymosin β4 spans cardiac repair (PMID 15565145, PMID 22236126), wound healing (PMID 27450738), corneal repair (PMID 11950239, PMID 27450739), and limb-ischemia angiogenesis (PMID 32945357). Research using the synthetic fragment specifically is more limited; the research-supply community generally regards fragment and full-length data as broadly applicable to each other, with the caveat that mechanism arms beyond actin-binding may differ between the two forms.

Why this matters in research context

The fragment-vs-full-length distinction matters for research protocols where mechanisms beyond actin-binding might be relevant. The integrin-linked kinase activation documented in the Bock-Marquette work (PMID 15565145) was characterised with full-length thymosin β4 — whether the fragment fully reproduces this arm is an open question. For protocols anchored to the actin-binding pharmacology, the fragment is broadly equivalent; for protocols studying the broader thymosin β4 mechanism map, the assumed equivalence carries a meaningful caveat.

Related compounds

TB-500 10mg — the compound covered by this answer
Wolverine Stack (BPC-157 + TB-500 blend) — combined-formulation single vial

References

Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem 2001;276(49):46094-46101. [PMID 11579089]
Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016;102:251-275. [PMID 27450738]
Lv S et al. Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. Int J Mol Med 2020;46(4):1347-1358. [PMID 32945357]

Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. TB-500 is sold strictly as a research-grade reagent for laboratory and bench research applications.